Analysts Set Omeros Co. (NASDAQ:OMER) PT at $22.50

Omeros Co. (NASDAQ:OMER) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $22.50.

Several research analysts have recently issued reports on the stock. Rodman & Renshaw began coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price on the stock. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. D. Boral Capital started coverage on Omeros in a research note on Monday, December 23rd. They set a “buy” rating and a $36.00 target price on the stock. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Thursday, December 19th.

Omeros Price Performance

OMER opened at $11.68 on Monday. The firm has a market cap of $676.86 million, a PE ratio of -5.06 and a beta of 1.96. The stock has a 50-day moving average price of $7.73 and a 200-day moving average price of $5.41. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60.

Institutional Investors Weigh In On Omeros

A number of institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in shares of Omeros by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 6,839 shares in the last quarter. State Street Corp increased its stake in Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 3,839 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Omeros by 4.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after purchasing an additional 18,454 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after purchasing an additional 31,081 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Omeros by 6.1% in the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after purchasing an additional 6,435 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.